« Back
Home /
Paritaprevir

Paritaprevir

Manufacturer	MedChem Express
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Amount	50 mg
Item no.	HY-12594-50mg
Targets	HCV Protease; HCV; SARS-CoV
CASRN	1216941-48-8
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor)[1][2][3][4].
StorageTemperature	4°C (Powder, sealed storage, away from moisture and light)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-anti-virus
MolecularWeight	765.88
Clinical_Information	Launched
Manufacturers Research_Area	Infection
Solubility	DMSO : ≥ 125 mg/mL\|H2O : ≥ 0.1 mg/mL
Manufacturers Target	HCV; HCV Protease; SARS-CoV
Pathway	Anti-infection; Metabolic Enzyme/Protease
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12594-50mg-safety-datasheet.pdf